Impact of Triple Drug Therapy on Morbidity, Mortality and Cost
Impact of Triple Drug Therapy on Morbidity, Mortality and Cost
Natalie Jahnke 1, Val Montessori 1, Robert Hogg 1, Aslam H. Anis 1, Michael OShaughnessy 1, Julio S.G. Montaner 1
1 NULL
*Correspondence: Aslam H. Anis, Email not available
Abstract
Two major advances emerged during the Vancouver International AIDS Conference in 1996: The recognition of the prognostic value of plasma viral load and the clinical benefit associated with triple drug combination therapy. These developments have led to a substantial change in the therapeutic management strategy for HIV disease. We have seen a dramatic decrease in HIV-related morbidity and mortality. Furthermore, preliminary results from pharmacoeconomic analyses indicate that the present therapeutic strategy is highly cost-effective.
Keywords: HIV. Morbidity. Mortality. Cost. Antiretroviral drugs.
